Alembic Pharmaceuticals Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Low return on equity: 3-year ROE 12.5%.
- Comfortable leverage: debt-to-equity of 0.24.
- Sales growth muted at 9.1% over 3 years.
- Weak cash conversion (CFO/OP 0.53).
- Trades below its industry P/E (22.8 vs 25.9).
- Dividend yield of 1.54%.
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Alembic Pharmaceuticals’ arm incorporates subsidiary in Dubai
The new entity aims to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company
- Alembic Pharma gets USFDA’s final nod for Ciprofloxacin and Dexamethasone Otic Suspension
The approved ANDA is therapeutically equivalent to the reference listed drug product, Ciprodex Otic Suspension, 0.3% / 0.1%, of Sandoz Inc
- USFDA completes inspection at Alembic Pharmaceuticals’ Bioequivalence Facility in Vadodara
The inspection was conducted at the company’s Bioequivalence Facility located in Vadodara and concluded with no Form 483 observations
- Alembic Pharmaceuticals incorporates subsidiary in Dubai
The new entity has been incorporated to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company
- Alembic Pharmaceuticals reports 12% rise in Q1 consolidated net profit
Consolidated total income of the company increased by 26.06% to Rs 2,164.70 crore in Q1FY27
- Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets
Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults
- Alembic Pharmaceuticals' partner NATCO gets USFDA’s tentative nod for Olaparib Tablets
The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg
- Alembic Pharmaceuticals gets USFDA’s final approval for Dapsone Gel
Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 7,345 | 6,672 | 6,229 | 5,653 | 5,306 |
| Other income | 55 | 48 | 29 | 3 | 50 |
| Total Income | 7,400 | 6,720 | 6,258 | 5,656 | 5,356 |
| Expenditure | 6,227 | 5,669 | 5,296 | 4,945 | 4,432 |
| Operating Profit | 1,173 | 1,051 | 962 | 711 | 925 |
| Interest | 94 | 79 | 56 | 50 | 18 |
| Depreciation | 319 | 279 | 273 | 275 | 287 |
| Profit before tax | 694 | 707 | 632 | 355 | 625 |
| Tax | 23 | 125 | 16 | 13 | 104 |
| Net Profit | 671 | 582 | 616 | 342 | 521 |
| EPS (₹) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 |
| Net margin % | 9.1 | 8.7 | 9.9 | 6.1 | 9.8 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 39 | 39 | 39 | 39 | 39 |
| Reserves | 5,636 | 5,152 | 4,779 | 4,331 | 5,198 |
| Net worth | 5,675 | 5,191 | 4,818 | 4,370 | 5,238 |
| Total sources | 6,169 | 5,361 | 4,991 | 4,546 | 5,406 |
| Net block | 3,081 | 2,524 | 2,547 | 2,398 | 1,798 |
| Capital work in progress | 683 | 837 | 524 | 601 | 2,304 |
| Investments | 156 | 158 | 126 | 150 | 153 |
| Inventory | 2,511 | 2,288 | 1,644 | 1,475 | 1,610 |
| Debtors | 1,466 | 1,400 | 1,025 | 1,046 | 807 |
| Cash & bank | 203 | 90 | 127 | 82 | 69 |
| Book value (₹) | 288.72 | 264.10 | 245.14 | 222.36 | 266.47 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 783 | 88 | 803 | 724 | 552 |
| From investing | -506 | -568 | -321 | -448 | -372 |
| From financing | -164 | 444 | -438 | -262 | -217 |
| Net change in cash | 113 | -37 | 45 | 14 | -37 |
| Free cash flow | 277 | -480 | 483 | 276 | 180 |
| Closing cash | 196 | 83 | 120 | 75 | 61 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 11.7 | 13.5 | 13.4 | 7.4 | 11.2 |
| ROE % | 12.3 | 11.6 | 13.4 | 7.1 | 10.1 |
| PAT margin % | 4.7 | 4.3 | 4.6 | 6.1 | 9.8 |
| EBIT margin % | 5.5 | 5.9 | 5.1 | 7.2 | 12.1 |
| Debt / equity | 0.24 | 0.23 | 0.09 | 0.15 | 0.12 |
| Current ratio | 1.73 | 1.67 | 2.07 | 1.78 | 1.63 |
| Interest cover | 8.41 | 9.98 | 12.24 | 8.07 | 36.27 |
| Sales growth % | 10.1 | 7.1 | 10.2 | 6.5 | -1.6 |
| Dividend per share (₹) | 12.00 | 11.00 | 11.00 | 8.00 | 10.00 |
| Payout % | 35.0 | 37.1 | 35.1 | 46.0 | 37.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Alembic Pharmaceuticals Ltd. (APLLTD) last traded at ₹781.30 on the NSE, down +0.84% on the session. Prices on this page are indicative and for information only.
Alembic Pharmaceuticals Ltd. has traded between ₹635.80 and ₹998.00 over the last 52 weeks on the NSE.
Alembic Pharmaceuticals Ltd. has a market capitalisation of about ₹15,356 crore.
Alembic Pharmaceuticals Ltd. trades at a P/E of 22.8, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for APLLTD from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Alembic Pharmaceuticals Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in